Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

Lucie de Beauchamp; Pablo Baquero; Elodie M. Kuntz; Eyal Gottlieb; G. Vignir Helgason

doi:10.1080/23723556.2017.1403532

Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

Lucie de Beauchamp, Pablo Baquero, Elodie M. Kuntz, Eyal Gottlieb, G. Vignir Helgason

Research output: Contribution to journal › Comment/debate

Abstract

We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

Original language	English
Article number	e1403532
Journal	Molecular and Cellular Oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.1080/23723556.2017.1403532
State	Published - 2 Jan 2018

Keywords

Cancer stem cells
CML
Metabolism
Imatinib
Leukaemia
OXPHOS
Tyrosine kinase inhibitor
Tigecycline
TCA cycle

ASJC Scopus subject areas

Molecular Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/23723556.2017.1403532

Fingerprint

Dive into the research topics of 'Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”'. Together they form a unique fingerprint.

Cite this

de Beauchamp, L., Baquero, P., Kuntz, E. M., Gottlieb, E., & Helgason, G. V. (2018). Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”. Molecular and Cellular Oncology, 5(1), Article e1403532. https://doi.org/10.1080/23723556.2017.1403532

de Beauchamp, Lucie ; Baquero, Pablo ; Kuntz, Elodie M. et al. / Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells" : “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”. In: Molecular and Cellular Oncology. 2018 ; Vol. 5, No. 1.

@article{b257757910e540349b4efd09bfcebc20,

title = "Auto-Commentary on: {"}Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells{"}: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”",

abstract = "We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.",

keywords = "Cancer stem cells, CML, Metabolism, Imatinib, Leukaemia, OXPHOS, Tyrosine kinase inhibitor, Tigecycline, TCA cycle",

author = "{de Beauchamp}, Lucie and Pablo Baquero and Kuntz, {Elodie M.} and Eyal Gottlieb and Helgason, {G. Vignir}",

note = "Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = jan,

day = "2",

doi = "10.1080/23723556.2017.1403532",

language = "אנגלית",

volume = "5",

number = "1",

}

de Beauchamp, L, Baquero, P, Kuntz, EM, Gottlieb, E & Helgason, GV 2018, 'Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”', Molecular and Cellular Oncology, vol. 5, no. 1, e1403532. https://doi.org/10.1080/23723556.2017.1403532

Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”. / de Beauchamp, Lucie; Baquero, Pablo; Kuntz, Elodie M. et al.
In: Molecular and Cellular Oncology, Vol. 5, No. 1, e1403532, 02.01.2018.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells"

T2 - “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

AU - de Beauchamp, Lucie

AU - Baquero, Pablo

AU - Kuntz, Elodie M.

AU - Gottlieb, Eyal

AU - Helgason, G. Vignir

PY - 2018/1/2

Y1 - 2018/1/2

N2 - We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

AB - We have recently uncovered an abnormal increase in mitochondrial oxidative metabolism in therapy-resistant chronic myeloid leukaemia stem cells (LSCs). By simultaneously disrupting mitochondrial respiration and inhibiting BCR-ABL kinase activity using the antibiotic tigecycline and imatinib respectively, we effectively eradicated LSCs and prevented disease relapse in pre-clinical animal models.

KW - Cancer stem cells

KW - CML

KW - Metabolism

KW - Imatinib

KW - Leukaemia

KW - OXPHOS

KW - Tyrosine kinase inhibitor

KW - Tigecycline

KW - TCA cycle

UR - http://www.scopus.com/inward/record.url?scp=85050757018&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1403532

DO - 10.1080/23723556.2017.1403532

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

SN - 2372-3556

VL - 5

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 1

M1 - e1403532

ER -

de Beauchamp L, Baquero P, Kuntz EM, Gottlieb E, Helgason GV. Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”. Molecular and Cellular Oncology. 2018 Jan 2;5(1):e1403532. doi: 10.1080/23723556.2017.1403532

Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells": “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this